| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthroplasty, Replacement, Knee | 24 | 2025 | 126 | 9.060 |
Why?
|
| Arthroplasty, Replacement, Hip | 16 | 2024 | 72 | 5.110 |
Why?
|
| Osteoarthritis, Knee | 16 | 2025 | 385 | 4.610 |
Why?
|
| Osteoarthritis, Hip | 8 | 2024 | 25 | 2.800 |
Why?
|
| Pain, Postoperative | 7 | 2025 | 162 | 2.300 |
Why?
|
| Hip Prosthesis | 13 | 2018 | 23 | 1.970 |
Why?
|
| Arthroplasty, Replacement | 5 | 2014 | 17 | 1.940 |
Why?
|
| Treatment Outcome | 32 | 2025 | 5680 | 1.670 |
Why?
|
| Pain Measurement | 10 | 2025 | 345 | 1.600 |
Why?
|
| Knee Joint | 11 | 2025 | 298 | 1.570 |
Why?
|
| Arthralgia | 4 | 2015 | 57 | 1.460 |
Why?
|
| Orthopedic Procedures | 5 | 2019 | 53 | 1.380 |
Why?
|
| Registries | 8 | 2015 | 888 | 1.380 |
Why?
|
| Orthopedics | 6 | 2019 | 33 | 1.320 |
Why?
|
| Patient Reported Outcome Measures | 7 | 2025 | 153 | 1.270 |
Why?
|
| Quality of Life | 6 | 2024 | 1228 | 1.270 |
Why?
|
| Activities of Daily Living | 5 | 2025 | 291 | 1.240 |
Why?
|
| Recovery of Function | 8 | 2025 | 288 | 1.220 |
Why?
|
| Prosthesis Failure | 14 | 2015 | 77 | 1.220 |
Why?
|
| Bone Cements | 9 | 2004 | 17 | 1.210 |
Why?
|
| Patient Satisfaction | 8 | 2024 | 433 | 1.170 |
Why?
|
| Disability Evaluation | 5 | 2015 | 217 | 1.070 |
Why?
|
| Patient Outcome Assessment | 3 | 2017 | 54 | 1.070 |
Why?
|
| Quality Indicators, Health Care | 3 | 2013 | 338 | 1.000 |
Why?
|
| Titanium | 7 | 2019 | 60 | 0.910 |
Why?
|
| Aged | 30 | 2025 | 14445 | 0.880 |
Why?
|
| Humans | 74 | 2025 | 63445 | 0.880 |
Why?
|
| Patient Selection | 3 | 2015 | 490 | 0.840 |
Why?
|
| Prospective Studies | 11 | 2024 | 3293 | 0.770 |
Why?
|
| Robotic Surgical Procedures | 1 | 2025 | 161 | 0.740 |
Why?
|
| Osteoarthritis | 4 | 2021 | 143 | 0.720 |
Why?
|
| Connective Tissue Diseases | 1 | 2021 | 11 | 0.700 |
Why?
|
| Polyethylene | 4 | 2018 | 10 | 0.700 |
Why?
|
| Talus | 1 | 2020 | 1 | 0.690 |
Why?
|
| Retinal Detachment | 1 | 2021 | 18 | 0.690 |
Why?
|
| Osteonecrosis | 1 | 2020 | 6 | 0.690 |
Why?
|
| Polyethylenes | 3 | 2015 | 6 | 0.680 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2021 | 48 | 0.670 |
Why?
|
| Middle Aged | 25 | 2025 | 17611 | 0.610 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2015 | 712 | 0.610 |
Why?
|
| Antifibrinolytic Agents | 1 | 2018 | 16 | 0.590 |
Why?
|
| Femur | 6 | 2014 | 54 | 0.590 |
Why?
|
| Tantalum | 2 | 2015 | 5 | 0.590 |
Why?
|
| Metal-on-Metal Joint Prostheses | 1 | 2018 | 1 | 0.590 |
Why?
|
| Critical Pathways | 1 | 2018 | 32 | 0.570 |
Why?
|
| Bone Morphogenetic Protein 2 | 8 | 2017 | 48 | 0.570 |
Why?
|
| Perioperative Care | 2 | 2018 | 85 | 0.570 |
Why?
|
| Osteoporotic Fractures | 1 | 2018 | 34 | 0.570 |
Why?
|
| Follow-Up Studies | 7 | 2025 | 2458 | 0.560 |
Why?
|
| Hip Fractures | 1 | 2018 | 77 | 0.530 |
Why?
|
| Male | 33 | 2025 | 29888 | 0.520 |
Why?
|
| Radiostereometric Analysis | 2 | 2015 | 2 | 0.500 |
Why?
|
| Biocompatible Materials | 6 | 2019 | 150 | 0.500 |
Why?
|
| Risk Adjustment | 2 | 2017 | 94 | 0.480 |
Why?
|
| Surveys and Questionnaires | 2 | 2013 | 2680 | 0.480 |
Why?
|
| Female | 29 | 2025 | 32877 | 0.480 |
Why?
|
| Patient Care Team | 1 | 2018 | 338 | 0.470 |
Why?
|
| Knee Prosthesis | 4 | 2001 | 11 | 0.470 |
Why?
|
| United States | 10 | 2025 | 7845 | 0.470 |
Why?
|
| Vancomycin | 4 | 2023 | 39 | 0.450 |
Why?
|
| Lymph Node Excision | 1 | 2015 | 46 | 0.450 |
Why?
|
| Musculoskeletal Diseases | 1 | 2015 | 103 | 0.450 |
Why?
|
| Postoperative Complications | 8 | 2025 | 1308 | 0.440 |
Why?
|
| Coated Materials, Biocompatible | 4 | 2019 | 46 | 0.440 |
Why?
|
| Femoral Fractures | 6 | 2015 | 23 | 0.430 |
Why?
|
| Workload | 1 | 2015 | 127 | 0.430 |
Why?
|
| Osteogenesis | 10 | 2019 | 143 | 0.430 |
Why?
|
| Quality Improvement | 2 | 2018 | 443 | 0.410 |
Why?
|
| Models, Psychological | 1 | 2013 | 97 | 0.410 |
Why?
|
| Adaptation, Psychological | 2 | 2013 | 266 | 0.410 |
Why?
|
| Postoperative Care | 3 | 2010 | 123 | 0.400 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 196 | 0.400 |
Why?
|
| Information Dissemination | 1 | 2013 | 116 | 0.390 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 49 | 0.380 |
Why?
|
| Low Back Pain | 1 | 2013 | 114 | 0.380 |
Why?
|
| Cardiovascular Diseases | 2 | 2018 | 835 | 0.380 |
Why?
|
| Bone Substitutes | 4 | 2014 | 16 | 0.380 |
Why?
|
| Chondrocytes | 4 | 2016 | 42 | 0.380 |
Why?
|
| Surgeons | 1 | 2015 | 183 | 0.370 |
Why?
|
| Tibia | 3 | 2020 | 70 | 0.370 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2013 | 125 | 0.370 |
Why?
|
| Schools, Medical | 1 | 2012 | 147 | 0.360 |
Why?
|
| Femur Head | 2 | 2009 | 3 | 0.350 |
Why?
|
| Emotions | 1 | 2013 | 223 | 0.350 |
Why?
|
| Osteolysis | 4 | 2010 | 18 | 0.350 |
Why?
|
| Patient Readmission | 1 | 2015 | 429 | 0.340 |
Why?
|
| Cartilage, Articular | 3 | 2017 | 78 | 0.340 |
Why?
|
| Range of Motion, Articular | 2 | 2008 | 104 | 0.340 |
Why?
|
| Bone and Bones | 4 | 2015 | 139 | 0.330 |
Why?
|
| Mental Health | 1 | 2013 | 371 | 0.330 |
Why?
|
| Staphylococcal Infections | 2 | 2023 | 129 | 0.330 |
Why?
|
| Cementation | 3 | 2004 | 3 | 0.330 |
Why?
|
| Narcotics | 1 | 2010 | 58 | 0.330 |
Why?
|
| Tissue Scaffolds | 4 | 2019 | 84 | 0.320 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 412 | 0.320 |
Why?
|
| Patient-Centered Care | 1 | 2012 | 254 | 0.320 |
Why?
|
| Walking | 2 | 2008 | 238 | 0.310 |
Why?
|
| Cohort Studies | 4 | 2024 | 2570 | 0.300 |
Why?
|
| Preoperative Care | 1 | 2010 | 193 | 0.300 |
Why?
|
| Evidence-Based Medicine | 3 | 2018 | 462 | 0.300 |
Why?
|
| Awards and Prizes | 2 | 2025 | 34 | 0.300 |
Why?
|
| Health Services Research | 3 | 2013 | 271 | 0.280 |
Why?
|
| Prosthesis Design | 8 | 2015 | 229 | 0.280 |
Why?
|
| Anti-Bacterial Agents | 4 | 2023 | 790 | 0.270 |
Why?
|
| Biomechanical Phenomena | 7 | 2015 | 270 | 0.270 |
Why?
|
| Fracture Healing | 3 | 2014 | 26 | 0.270 |
Why?
|
| Time Factors | 9 | 2015 | 3768 | 0.260 |
Why?
|
| Predictive Value of Tests | 3 | 2015 | 1094 | 0.260 |
Why?
|
| Prostheses and Implants | 2 | 2019 | 71 | 0.250 |
Why?
|
| Pain | 2 | 2022 | 406 | 0.250 |
Why?
|
| Monitoring, Ambulatory | 1 | 2006 | 57 | 0.250 |
Why?
|
| Transforming Growth Factor beta | 4 | 2015 | 172 | 0.240 |
Why?
|
| Exercise Therapy | 1 | 2006 | 104 | 0.240 |
Why?
|
| Documentation | 1 | 2006 | 128 | 0.240 |
Why?
|
| Aged, 80 and over | 10 | 2017 | 5461 | 0.230 |
Why?
|
| Elective Surgical Procedures | 2 | 2017 | 123 | 0.230 |
Why?
|
| Preoperative Period | 2 | 2016 | 71 | 0.230 |
Why?
|
| Operative Time | 1 | 2025 | 92 | 0.230 |
Why?
|
| Adhesiveness | 1 | 2004 | 13 | 0.220 |
Why?
|
| Hydroxyapatites | 2 | 2014 | 8 | 0.220 |
Why?
|
| Polymethacrylic Acids | 2 | 2014 | 10 | 0.220 |
Why?
|
| Patient Compliance | 1 | 2006 | 360 | 0.210 |
Why?
|
| Metals | 2 | 2018 | 65 | 0.210 |
Why?
|
| Bone Morphogenetic Protein 7 | 2 | 2017 | 16 | 0.210 |
Why?
|
| Prevalence | 2 | 2022 | 1380 | 0.200 |
Why?
|
| Stress, Mechanical | 5 | 2005 | 110 | 0.200 |
Why?
|
| Back Pain | 1 | 2023 | 51 | 0.200 |
Why?
|
| Bone Transplantation | 2 | 2014 | 30 | 0.190 |
Why?
|
| Rats | 9 | 2023 | 1980 | 0.190 |
Why?
|
| Durapatite | 2 | 2015 | 27 | 0.190 |
Why?
|
| Recombinant Proteins | 7 | 2017 | 702 | 0.190 |
Why?
|
| Staphylococcus aureus | 2 | 2023 | 176 | 0.190 |
Why?
|
| Bone Regeneration | 2 | 2019 | 15 | 0.180 |
Why?
|
| Length of Stay | 1 | 2025 | 812 | 0.180 |
Why?
|
| Arthritis | 2 | 2021 | 53 | 0.170 |
Why?
|
| Sex Factors | 1 | 2024 | 980 | 0.170 |
Why?
|
| Bone Morphogenetic Proteins | 3 | 2019 | 62 | 0.170 |
Why?
|
| Adult | 9 | 2015 | 16823 | 0.170 |
Why?
|
| Ossification, Heterotopic | 3 | 1991 | 13 | 0.170 |
Why?
|
| Cell Differentiation | 9 | 2017 | 1353 | 0.160 |
Why?
|
| Menisci, Tibial | 2 | 2017 | 25 | 0.160 |
Why?
|
| Weight-Bearing | 4 | 2005 | 35 | 0.160 |
Why?
|
| Animals | 22 | 2023 | 20660 | 0.160 |
Why?
|
| Medicare | 1 | 2024 | 612 | 0.160 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2017 | 85 | 0.150 |
Why?
|
| Reoperation | 4 | 2012 | 293 | 0.150 |
Why?
|
| Osteoblasts | 3 | 2009 | 198 | 0.150 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 182 | 0.150 |
Why?
|
| Tranexamic Acid | 1 | 2018 | 7 | 0.150 |
Why?
|
| Denmark | 1 | 2018 | 17 | 0.150 |
Why?
|
| Surface Properties | 6 | 2014 | 278 | 0.150 |
Why?
|
| Materials Testing | 4 | 2004 | 85 | 0.150 |
Why?
|
| Cadaver | 5 | 2005 | 128 | 0.140 |
Why?
|
| Workflow | 1 | 2018 | 70 | 0.140 |
Why?
|
| Biofilms | 1 | 2019 | 82 | 0.140 |
Why?
|
| Physical Examination | 2 | 2016 | 111 | 0.140 |
Why?
|
| Blood Transfusion | 1 | 2018 | 162 | 0.140 |
Why?
|
| Tensile Strength | 3 | 2004 | 29 | 0.140 |
Why?
|
| Musculoskeletal Pain | 1 | 2017 | 28 | 0.130 |
Why?
|
| Bone Marrow Cells | 4 | 2015 | 238 | 0.130 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2009 | 152 | 0.130 |
Why?
|
| Cross-Cultural Comparison | 1 | 2017 | 47 | 0.130 |
Why?
|
| Radiography | 6 | 2009 | 550 | 0.130 |
Why?
|
| Aging | 3 | 2017 | 745 | 0.130 |
Why?
|
| Obesity, Morbid | 1 | 2017 | 98 | 0.120 |
Why?
|
| Blood Transfusion, Autologous | 1 | 1995 | 6 | 0.120 |
Why?
|
| Mice | 12 | 2023 | 10844 | 0.120 |
Why?
|
| Analysis of Variance | 4 | 2004 | 608 | 0.120 |
Why?
|
| Cells, Cultured | 7 | 2016 | 2157 | 0.120 |
Why?
|
| Retrospective Studies | 3 | 2015 | 6657 | 0.120 |
Why?
|
| Lactates | 1 | 2015 | 29 | 0.120 |
Why?
|
| Single-Blind Method | 1 | 2015 | 144 | 0.110 |
Why?
|
| Product Recalls and Withdrawals | 1 | 2014 | 1 | 0.110 |
Why?
|
| Health Status Indicators | 1 | 2015 | 93 | 0.110 |
Why?
|
| Disease Management | 1 | 2016 | 232 | 0.110 |
Why?
|
| Unnecessary Procedures | 1 | 2015 | 49 | 0.110 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2015 | 83 | 0.110 |
Why?
|
| Medical Audit | 1 | 2015 | 65 | 0.110 |
Why?
|
| Methacrylates | 1 | 2014 | 39 | 0.110 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2016 | 219 | 0.110 |
Why?
|
| Alloys | 4 | 2019 | 29 | 0.110 |
Why?
|
| Time-to-Treatment | 1 | 2015 | 112 | 0.110 |
Why?
|
| Polyethylene Glycols | 1 | 2015 | 167 | 0.100 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2013 | 42 | 0.100 |
Why?
|
| Joint Diseases | 1 | 1993 | 20 | 0.100 |
Why?
|
| Hip Joint | 1 | 1993 | 36 | 0.100 |
Why?
|
| Risk Factors | 4 | 2017 | 5353 | 0.100 |
Why?
|
| RANK Ligand | 2 | 2009 | 22 | 0.100 |
Why?
|
| United States Agency for Healthcare Research and Quality | 1 | 2012 | 30 | 0.100 |
Why?
|
| Program Development | 1 | 2013 | 207 | 0.100 |
Why?
|
| Physician-Patient Relations | 1 | 2015 | 419 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 311 | 0.090 |
Why?
|
| Membrane Proteins | 2 | 2009 | 895 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2013 | 308 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2017 | 621 | 0.090 |
Why?
|
| Renal Dialysis | 1 | 1993 | 196 | 0.090 |
Why?
|
| Apatites | 1 | 2011 | 3 | 0.090 |
Why?
|
| Logistic Models | 1 | 2015 | 1276 | 0.090 |
Why?
|
| Patient Dropouts | 1 | 2011 | 49 | 0.090 |
Why?
|
| Health Care Costs | 1 | 2013 | 211 | 0.090 |
Why?
|
| Interprofessional Relations | 1 | 2012 | 135 | 0.090 |
Why?
|
| Quality of Health Care | 1 | 2015 | 519 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 2172 | 0.090 |
Why?
|
| Drug Carriers | 1 | 2013 | 178 | 0.090 |
Why?
|
| Cell Proliferation | 5 | 2017 | 988 | 0.090 |
Why?
|
| Databases, Factual | 1 | 2015 | 873 | 0.090 |
Why?
|
| Self Report | 1 | 2013 | 375 | 0.090 |
Why?
|
| Data Collection | 1 | 2012 | 383 | 0.090 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 597 | 0.090 |
Why?
|
| Communication | 1 | 2015 | 572 | 0.090 |
Why?
|
| Boronic Acids | 1 | 2010 | 28 | 0.080 |
Why?
|
| Pyrazines | 1 | 2010 | 34 | 0.080 |
Why?
|
| Electronic Health Records | 1 | 2013 | 361 | 0.080 |
Why?
|
| Behavior Therapy | 1 | 2011 | 167 | 0.080 |
Why?
|
| Interleukin-1 | 1 | 2010 | 156 | 0.080 |
Why?
|
| Body Mass Index | 2 | 2017 | 866 | 0.080 |
Why?
|
| Bone Density | 3 | 2015 | 134 | 0.080 |
Why?
|
| Receptors, Leukotriene | 1 | 2009 | 2 | 0.080 |
Why?
|
| Femur Head Necrosis | 1 | 2009 | 3 | 0.080 |
Why?
|
| Wnt Proteins | 2 | 2009 | 98 | 0.080 |
Why?
|
| Leukotriene Antagonists | 1 | 2009 | 8 | 0.080 |
Why?
|
| Protease Inhibitors | 1 | 2010 | 102 | 0.080 |
Why?
|
| Tetracycline | 1 | 2009 | 24 | 0.080 |
Why?
|
| In Vitro Techniques | 4 | 2005 | 490 | 0.080 |
Why?
|
| Algorithms | 1 | 2015 | 1003 | 0.080 |
Why?
|
| Elastomers | 1 | 2009 | 7 | 0.080 |
Why?
|
| Minerals | 1 | 2009 | 20 | 0.080 |
Why?
|
| Bone Remodeling | 1 | 2009 | 25 | 0.080 |
Why?
|
| Tibial Fractures | 1 | 2009 | 13 | 0.080 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2009 | 33 | 0.080 |
Why?
|
| Sterilization | 2 | 2001 | 15 | 0.080 |
Why?
|
| Decision Making | 1 | 2012 | 407 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 1553 | 0.070 |
Why?
|
| Fractures, Bone | 1 | 2009 | 143 | 0.070 |
Why?
|
| Health Behavior | 1 | 2011 | 469 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2015 | 2079 | 0.070 |
Why?
|
| Equipment Failure Analysis | 2 | 2005 | 75 | 0.070 |
Why?
|
| Calcium | 1 | 2011 | 575 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2010 | 525 | 0.070 |
Why?
|
| Dexamethasone | 1 | 2008 | 205 | 0.070 |
Why?
|
| Compressive Strength | 3 | 2013 | 18 | 0.070 |
Why?
|
| Disease Models, Animal | 4 | 2017 | 2187 | 0.070 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2011 | 480 | 0.070 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2008 | 172 | 0.070 |
Why?
|
| Choristoma | 1 | 1986 | 22 | 0.060 |
Why?
|
| Cell Survival | 3 | 2015 | 575 | 0.060 |
Why?
|
| Self Disclosure | 1 | 2006 | 37 | 0.060 |
Why?
|
| Osseointegration | 2 | 2014 | 5 | 0.060 |
Why?
|
| Societies, Medical | 1 | 2008 | 379 | 0.060 |
Why?
|
| Carrier Proteins | 3 | 2010 | 707 | 0.060 |
Why?
|
| Gene Expression Regulation | 4 | 2017 | 1617 | 0.060 |
Why?
|
| Polymethyl Methacrylate | 1 | 2004 | 14 | 0.060 |
Why?
|
| Statistics, Nonparametric | 1 | 2004 | 215 | 0.050 |
Why?
|
| Finite Element Analysis | 1 | 2003 | 13 | 0.050 |
Why?
|
| Micrococcal Nuclease | 1 | 2023 | 13 | 0.050 |
Why?
|
| Motor Activity | 1 | 2006 | 346 | 0.050 |
Why?
|
| Collagen Type I | 2 | 2017 | 41 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2004 | 498 | 0.050 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2004 | 390 | 0.050 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 937 | 0.050 |
Why?
|
| Fractures, Stress | 1 | 2003 | 12 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 3 | 2017 | 3396 | 0.050 |
Why?
|
| Tissue Engineering | 2 | 2015 | 141 | 0.050 |
Why?
|
| Health Status | 1 | 2005 | 436 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2006 | 1008 | 0.050 |
Why?
|
| Microscopy, Electron, Scanning | 2 | 2013 | 109 | 0.050 |
Why?
|
| Comorbidity | 1 | 2005 | 1120 | 0.050 |
Why?
|
| Social Support | 1 | 2004 | 371 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2010 | 1198 | 0.040 |
Why?
|
| Anxiety | 1 | 2004 | 425 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2009 | 3035 | 0.040 |
Why?
|
| Blood Loss, Surgical | 2 | 1997 | 65 | 0.040 |
Why?
|
| Radiotherapy Dosage | 2 | 1991 | 84 | 0.040 |
Why?
|
| Hypertrophy | 2 | 2009 | 30 | 0.040 |
Why?
|
| Mental Disorders | 1 | 2005 | 791 | 0.040 |
Why?
|
| Dalteparin | 1 | 1997 | 2 | 0.030 |
Why?
|
| Thrombophlebitis | 1 | 1997 | 14 | 0.030 |
Why?
|
| Premedication | 1 | 1997 | 20 | 0.030 |
Why?
|
| RNA, Messenger | 3 | 2008 | 1537 | 0.030 |
Why?
|
| Depression | 1 | 2004 | 894 | 0.030 |
Why?
|
| Periosteum | 1 | 2017 | 5 | 0.030 |
Why?
|
| Osteophyte | 1 | 2017 | 5 | 0.030 |
Why?
|
| Osteocalcin | 1 | 2017 | 47 | 0.030 |
Why?
|
| Cell Line | 2 | 2013 | 2040 | 0.030 |
Why?
|
| Switzerland | 1 | 2017 | 14 | 0.030 |
Why?
|
| Rats, Inbred BB | 1 | 2017 | 134 | 0.030 |
Why?
|
| Femur Neck | 1 | 1997 | 12 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2017 | 78 | 0.030 |
Why?
|
| Incidence | 1 | 2001 | 1377 | 0.030 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2017 | 51 | 0.030 |
Why?
|
| Organ Size | 1 | 2017 | 170 | 0.030 |
Why?
|
| Bone Plates | 1 | 1997 | 37 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2017 | 185 | 0.030 |
Why?
|
| PPAR gamma | 1 | 2017 | 76 | 0.030 |
Why?
|
| Warfarin | 1 | 1997 | 111 | 0.030 |
Why?
|
| Fracture Fixation, Internal | 1 | 1997 | 65 | 0.030 |
Why?
|
| Transforming Growth Factor beta3 | 1 | 2016 | 3 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 1997 | 268 | 0.030 |
Why?
|
| Knee Injuries | 1 | 2016 | 48 | 0.030 |
Why?
|
| Acetabulum | 1 | 2015 | 3 | 0.030 |
Why?
|
| Postoperative Period | 1 | 1995 | 137 | 0.030 |
Why?
|
| Somatomedins | 1 | 1994 | 4 | 0.030 |
Why?
|
| Computer Simulation | 1 | 1997 | 477 | 0.030 |
Why?
|
| Torsion, Mechanical | 1 | 2014 | 4 | 0.030 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2015 | 37 | 0.030 |
Why?
|
| Chemokine CXCL12 | 1 | 2014 | 18 | 0.030 |
Why?
|
| X-Ray Microtomography | 1 | 2014 | 25 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2016 | 309 | 0.030 |
Why?
|
| Calcium Phosphates | 1 | 2014 | 8 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2016 | 265 | 0.030 |
Why?
|
| Macrophages | 2 | 2010 | 1039 | 0.030 |
Why?
|
| Cattle | 1 | 2015 | 310 | 0.030 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2013 | 47 | 0.030 |
Why?
|
| Cell Transdifferentiation | 1 | 2013 | 15 | 0.030 |
Why?
|
| Elasticity | 1 | 2013 | 43 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 618 | 0.030 |
Why?
|
| Anticoagulants | 1 | 1997 | 495 | 0.030 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2013 | 35 | 0.030 |
Why?
|
| beta 2-Microglobulin | 1 | 1993 | 49 | 0.030 |
Why?
|
| Solubility | 1 | 2013 | 180 | 0.020 |
Why?
|
| Drug Compounding | 1 | 2013 | 76 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 2013 | 115 | 0.020 |
Why?
|
| Mice, Knockout | 2 | 2009 | 2109 | 0.020 |
Why?
|
| Amyloid | 1 | 1993 | 70 | 0.020 |
Why?
|
| Age Factors | 1 | 2017 | 1558 | 0.020 |
Why?
|
| Directive Counseling | 1 | 2011 | 39 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2005 | 1147 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2011 | 135 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2010 | 36 | 0.020 |
Why?
|
| Bortezomib | 1 | 2010 | 56 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2011 | 201 | 0.020 |
Why?
|
| Neutrophil Infiltration | 1 | 2010 | 60 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2010 | 98 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2010 | 190 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2010 | 200 | 0.020 |
Why?
|
| Leukotriene B4 | 1 | 2009 | 12 | 0.020 |
Why?
|
| Hydroxyurea | 1 | 2009 | 19 | 0.020 |
Why?
|
| Myoblasts, Skeletal | 1 | 2009 | 12 | 0.020 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2009 | 10 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2010 | 189 | 0.020 |
Why?
|
| Sulfides | 1 | 2009 | 23 | 0.020 |
Why?
|
| Bony Callus | 1 | 2009 | 3 | 0.020 |
Why?
|
| Acetates | 1 | 2009 | 33 | 0.020 |
Why?
|
| Osteoclasts | 1 | 2009 | 48 | 0.020 |
Why?
|
| Freeze Drying | 1 | 2009 | 15 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2010 | 208 | 0.020 |
Why?
|
| Powders | 1 | 2009 | 20 | 0.020 |
Why?
|
| Quinolines | 1 | 2009 | 45 | 0.020 |
Why?
|
| Cyclopropanes | 1 | 2009 | 50 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2010 | 319 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2010 | 519 | 0.020 |
Why?
|
| Cartilage | 1 | 2009 | 35 | 0.020 |
Why?
|
| Risk | 2 | 1987 | 377 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2009 | 68 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2008 | 35 | 0.020 |
Why?
|
| Osteopontin | 1 | 2008 | 21 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 109 | 0.020 |
Why?
|
| Steel | 1 | 2008 | 1 | 0.020 |
Why?
|
| Chromium | 1 | 2008 | 5 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2013 | 707 | 0.020 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2010 | 258 | 0.020 |
Why?
|
| Cobalt | 1 | 2008 | 16 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2008 | 165 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2009 | 270 | 0.020 |
Why?
|
| Water | 1 | 2009 | 309 | 0.020 |
Why?
|
| Hip | 1 | 1987 | 7 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 1644 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1986 | 104 | 0.020 |
Why?
|
| SOX9 Transcription Factor | 1 | 2006 | 7 | 0.020 |
Why?
|
| Collagen Type X | 1 | 2006 | 4 | 0.020 |
Why?
|
| Collagen Type II | 1 | 2006 | 12 | 0.020 |
Why?
|
| Growth Plate | 1 | 2006 | 9 | 0.020 |
Why?
|
| High Mobility Group Proteins | 1 | 2006 | 24 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 1469 | 0.020 |
Why?
|
| beta Catenin | 1 | 2006 | 96 | 0.020 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 1 | 2006 | 142 | 0.010 |
Why?
|
| Hedgehog Proteins | 1 | 2006 | 111 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 1986 | 125 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 663 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 542 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2006 | 612 | 0.010 |
Why?
|
| Pressure | 1 | 2005 | 79 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2010 | 795 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2006 | 394 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2006 | 311 | 0.010 |
Why?
|
| Models, Biological | 1 | 2009 | 1180 | 0.010 |
Why?
|
| Exercise | 1 | 2011 | 942 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 896 | 0.010 |
Why?
|
| Biomarkers | 1 | 2008 | 1408 | 0.010 |
Why?
|
| Motion | 1 | 2003 | 59 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2006 | 770 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2006 | 642 | 0.010 |
Why?
|
| Reference Values | 1 | 2003 | 331 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2002 | 251 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2003 | 401 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2005 | 1654 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2006 | 1513 | 0.010 |
Why?
|
| Hemorrhage | 1 | 1997 | 267 | 0.010 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 1994 | 6 | 0.010 |
Why?
|
| Radioligand Assay | 1 | 1994 | 24 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1994 | 63 | 0.010 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 1994 | 42 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 1994 | 53 | 0.010 |
Why?
|
| Bone Diseases, Metabolic | 1 | 1994 | 20 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1994 | 187 | 0.010 |
Why?
|
| Absorptiometry, Photon | 1 | 1994 | 76 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1994 | 231 | 0.010 |
Why?
|
| Rabbits | 1 | 1994 | 333 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1994 | 458 | 0.010 |
Why?
|
| Hyperostosis, Diffuse Idiopathic Skeletal | 1 | 1987 | 1 | 0.000 |
Why?
|
| Spondylitis, Ankylosing | 1 | 1987 | 24 | 0.000 |
Why?
|